Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, Osaka, 541-8567, Japan.
Eur Radiol. 2020 Oct;30(10):5768-5776. doi: 10.1007/s00330-020-06953-z. Epub 2020 May 21.
It is challenging to know at the first which patients with desmoid fibromatosis (DF) are better suited to conservative or aggressive treatment. To investigate whether the low signal intensity bundles on T1- or T2-weighted images (WI), termed the "black fiber sign (BFS)," can predict non-progressive behavior in the conservative approach.
This retrospective study included 59 patients with primary DF managed with wait-and-see approach from 2005 to 2018 and serial MR images were analyzed. Three observers blinded to the patient information verified the presence or absence of BFS on baseline T1 or T2WI. The likelihood of progression-free survival (PFS) after ascertaining the presence or absence of the BFS was estimated using the Kaplan-Meier method and analyzed with the log-rank test.
PFS was significantly higher in cases with BFS than without BFS on T1WI (p < 0.01), but there was no significant difference in PFS between cases with and without BFS on T2WI. Multivariable Cox proportional hazards analysis revealed that the absence of BFS on T1WI was a high-risk factor for progression (hazard ratio, 14.9; p < 0.01). Drastic tumor regression was apparent with significantly increased low-signal area in cases with BFS on T1WI. Intra- and interobserver reliabilities of BFS on T1WI were in almost-perfect agreement (κ > 0.8).
Our retrospective observational data support that presence of BFS in baseline MRI may be a predictor for progression-free survival of DF. BFS on T1WI is easily identifiable and can be utilized clinically in patients with DF.
• We proposed a new imaging marker for prediction of desmoid fibromatosis progression. • The absence of black fiber sign predicted a high risk of disease progression.
对于患有硬纤维瘤(DF)的患者,最初很难确定哪些患者更适合保守治疗或积极治疗。本研究旨在探讨 T1 或 T2 加权图像(WI)上低信号束(称为“黑纤维征(BFS)”)是否可以预测保守治疗中的非进展性行为。
本回顾性研究纳入了 2005 年至 2018 年期间采用观察等待方式治疗的 59 例原发性 DF 患者,对其进行了连续 MRI 分析。3 位观察者对患者信息进行了盲法评估,以确定基线 T1 或 T2WI 是否存在 BFS。使用 Kaplan-Meier 法估计有无 BFS 时无进展生存(PFS)的可能性,并使用对数秩检验进行分析。
T1WI 存在 BFS 的患者 PFS 显著高于不存在 BFS 的患者(p<0.01),但 T2WI 上存在和不存在 BFS 的患者 PFS 无显著差异。多变量 Cox 比例风险分析显示,T1WI 上不存在 BFS 是进展的高危因素(风险比,14.9;p<0.01)。T1WI 上存在 BFS 的患者肿瘤明显消退,低信号区域显著增加。T1WI 上 BFS 的观察者内和观察者间可靠性几乎达到完美一致(κ>0.8)。
本回顾性观察数据支持基线 MRI 上存在 BFS 可能是预测 DF 无进展生存的一个指标。T1WI 上的 BFS 易于识别,可用于 DF 患者的临床实践。
• 我们提出了一种新的影像学标志物来预测硬纤维瘤的进展。• 黑纤维征的缺失预测了疾病进展的高风险。